RSS

antibiotics

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

A study has been published looking at the mechanism of action of odilorhabdins — a new class of antibiotics — to combat antibiotic resistance, disclosed Nosopharm and the University of Illinois at Chicago (UIC) more

News

Swiss-based specialty pharma company, Polyphor, has announced that the first patient has been enrolled in the Phase III clinical trial for murepavadin — a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia more

News

A biotech company, Deinove, has signed an exclusive research licence with Italian biopharma company, Naicons, to aid in the discovery of new antibiotics through the Antibiotics against Resistant Infectious Germs (AGIR) project. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Recent research from a team at Rockefeller University has uncovered natural compounds in soil samples that may be useful in the treatment of several bacterial infections that have become resistant to multiple antibiotics. more

News

Debiopharm Group, international biopharmaceutical group, has continued its efforts in the fight against antibiotic resistance by investing in antibiotic development through acquiring a minority stake in ABAC Therapeutics. more

News

A company dedicated to the research and development of new anti-infective drugs, Nosopharm, has received funding from Bpifrance worth €1 million in the form of an interest-free loan. more

News

Steps are being taken by pharma to openly share data on changes to the susceptibility of pathogens to antibiotics around the world as part of a pilot project to tackle the growing problem of drug-resistant infections. more

News

The Access to Medicine Foundation has published an independent analysis of the efforts made by pharma companies to address the issue of drug resistant infections. more

Analysis

In this case study, BHS-Sonthofen looks at how production process redesign, implementing a rotary pressure filter, can improve yield. more

Opinion

The AMR Centre (AMRC) and EligoChem have entered into an agreement for the co-development of antimicrobial peptides to treat drug-resistant Gram-negative bacteria, such as E. coli. more

News

Speaking at the launch of the AMR Centre in Alderley Park, Cheshire, two experts in the field of antimicrobial resistance (AMR) have raised concerns that research into this serious public health threat are lagging and a ‘renewed focus’ is essential. more

News

Two new research polls, commissioned by The Longitude Prize, have demonstrated that even though there has been a reduction in the number of prescribed antibiotics GPs are still inclined to err on the side of caution. more

Analysis

Speaking at the World Antibiotic Awareness Week, Eriko Takano, professor of synthetic biology at The University of Manchester, has given a glimmer of hope in the antibiotics production crisis — robotics! more

News

British biopharmaceuticals company, Helperby Therapeutics, has developed a sustainable solution to combat antimicrobial resistance — Antibiotic Resistance Breakers (ARBs) — which may reach the market as early as 2020. more

Technology

A joint research project has been initiated by Medicines Discovery Catapult and ANTRUK to tackle the rapidly growing issue of antimicrobial resistance. more

News

A specialist in therapeutic approaches to treat resistant bacterial infections, Mutabilis has been selected to join the European consortium ENABLE — aimed at developing antibiotics to tackle infections caused by multi-resistant gram-negative bacteria more

News

The AMR Centre and Swedish company Medivir have signed an exclusive licensing agreement aimed at tackling NDM-1 and other metallo-β-lactamases, which make bacteria resistant to widely-used antibiotics. more

News

Cheshire-based R&D facility for new antibiotics and diagnostics, the AMR Centre, has signed a deal with US biotech company, Microbiotix, for the co-development of a bacterial virulence drug candidate. more

News